{
    "project_id": "171003",
    "broad_study_type": "other",
    "narrow_study_type": "biomarker_discovery",
    "trial_phase": "N/A",
    "observational_timeframe": "N/A",
    "justification": "The goal of our research is to develop a clinical assay or diagnostic test to detect the presence of variants in the reductase enzymes that can be used as markers to predict the development of prostate cancer or anthracycline induced heart toxicity.",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "Knowing the genetic make up of these enzyme pathways in patients will permit physicians to choose better therapies to significantly reduce mortality and morbidity in patients with these, and potentially other, types of cancer.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "unclear",
    "gender_focus": "men",
    "vulnerable_populations": "no",
    "rare_disease": "no",
    "population_description": "patients with prostate cancer, breast cancer, or leukemias",
    "intervention_category": "N/A",
    "intervention_name": "N/A",
    "control_type": "no_control",
    "dose_response": "no",
    "combination_therapy": "no",
    "personalized_medicine": "yes",
    "primary_outcome": "genetic variants in reductase enzymes as biomarkers",
    "primary_outcome_type": "biomarker",
    "safety_focus": "no",
    "quality_of_life": "no",
    "biomarker_endpoints": "yes",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "no",
    "budget_impact": "no",
    "health_technology_assessment": "no",
    "resource_utilization": "no",
    "productivity_outcomes": "no",
    "implementation_science": "no",
    "policy_evaluation": "no",
    "health_system_integration": "no",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "no",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "no",
    "community_based": "no",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "yes",
    "ethics_focus": "no",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "oncology",
    "disease_stage": "unclear",
    "comorbidity_focus": "yes",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "yes",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "medium_term",
    "multicenter": "no",
    "healthcare_setting": "laboratory",
    "disease_area": "prostate cancer, breast cancer, leukemia, anthracycline-induced cardiotoxicity",
    "methodology_innovation": "examining the effect of genetic variation in reductase enzyme pathways on hormone levels and drug metabolism as potential biomarkers for cancer risk and toxicity",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 